Unraveling BOLD-100 synergistic potential in pleural mesothelioma treatment: an in vitro study

Investigational New Drugs 2025 May 8 [Link] Gregorio Bonsignore, Elia Ranzato , Simona Martinotti Abstract Pleural mesothelioma (PM) is a rare cancer affecting the pleural layer on the body’s serosal surfaces. Exposure to asbestos fibers, a naturally occurring fibrous material with insulating characteristics, contributes to PM’s prevalence. PM has a long latency period, making major…

Read More

Enhanced Detection of Recurrent Diffuse Malignant Peritoneal Mesothelioma Using 68 Ga-FAPI PET/CT Compared to 18 F-FDG PET/CT: A Case Report

World Journal of Nuclear Medicine 2025 March 12 [Link] Marwah Abdulrahman, Ula Al-Rasheed, Ali Dabous, Akram Al-Ibraheem Abstract Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive subtype of epithelioid mesothelioma that arises from the lining of the abdominal cavity. While the applications of traditional fluorine-18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography…

Read More

Oncological Outcomes Of Radical Surgery With And Without Induction And Adjuvant Chemotherapy In Mesothelioma Patients – 8-Year Experience In A Single Center

Portuguese Journal of Cardiac Thoracic & Vascular Surgery 2025 April 29 [Link] Agata Nawojowska, Samuel Mendes, Marion Gaspar, Daniel Cabral, Cristina Rodrigues, Mariana Antunes, Magda Alvoeiro, Telma Calado, Francisco Félix Abstract Introduction: Mesothelioma is a devastating, insidious disease with a long latency period. Its peak incidence occurs in the 5th and 6th decades of life,…

Read More

The Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma

Cancers 2025 April 20 [Link] Berta Mosleh, Katharina Sinn, Anna Cho, Anton Reiner, Ariane Steindl, Christian Lang, Sabine Zöchbauer-Müller, Karin Dieckmann, Joachim Widder, Helmut Prosch, Balazs Dome, Karin Schelch, Clemens Aigner, Thomas Klikovits, Michal Benej, Stefan Watzka, Martin Filipits, Servet Bölükbas, Pavla Sarova, Daniela Gompelmann, Michael Grusch, Mir Alireza Hoda Abstract Background/objectives: Malignant pleural mesothelioma…

Read More

Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook

Current Treatment Options in Oncology 2025 May [Link] Giovanni Luca Ceresoli, Letizia Gianoncelli Abstract Pleural mesothelioma is an incurable cancer with unmet diagnostic and therapeutic needs. Due to its pattern of local spread, few patients are candidates for multimodality treatment and thus most patients only receive systemic therapy. Chemotherapy (pemetrexed plus platinum) was standard of…

Read More

Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma

Lung Cancer 2025 May [Link] Ernest Nadal, Paloma Martín-Martorell, Jose Carlos Benítez, Maria Ángeles Sala, Susana Cedrés, Carlos Álvarez, Manuel Dómine, Elia Sais 8, Maria Saigí, Rafael López, Laia Vilà, Bartomeu Massutí, Rosario García-Campelo, Andres Mesas-Ruiz, Amelia Insa, Sílvia Plans-Marín, Sara Hijazo-Pechero, Cristina Muñoz-Pinedo, Jesús Brenes, Mariano Provencio Abstract Objectives: We aimed to evaluate the…

Read More

Cytoplasmic HuR Expression Enhances Chemoresistance in Pleural Mesothelioma Through Increased Expression of CALB2, Promotion of the E2F Pathway, and Suppression of the p53 Pathway

Thoracic Cancer 2025 April [Link] Susumu Kirimura, Morito Kurata, Hironori Ishibashi, Yusuke Taniguchi, Yuko Kinowaki, Keisuke Sugita, Kenichi Okubo Abstract Introduction: Chemotherapy is crucial for treating pleural mesothelioma; however, the outcomes are poor, necessitating an urgent need to study the mechanism of chemotherapy resistance in mesothelioma cells. Human antigen R (HuR), an RNA-binding protein and…

Read More

Radical hemithorax radiotherapy induces an increase in circulating PD-1+ T lymphocytes and in the soluble levels of PD-L1 in malignant pleural mesothelioma patients: a possible synergy with PD-1/PD-L1 targeting treatment?

Frontiers in Immunology 2025 April 1 [Link] Alberto Revelant, Francesca Gessoni, Marcella Montico, Raja Dhibi, Giulia Brisotto, Mariateresa Casarotto, Martina Zanchetta, Veronica Paduano, Filippo Sperti, Chiara Evangelista, Fabiana Giordari, Valli De Re, Marco Trovò, Emilio Minatel, Maurizio Mascarin, Agostino Steffan, Elena Muraro Abstract Malignant Pleural Mesothelioma (MPM) is an aggressive tumor associated with asbestos exposure,…

Read More

Hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma after cytoreductive surgical procedures: a systematic review

World Journal of Surgical Oncology 2025 April 9 [Link] Hany Hasan Elsayed, Mohamed Elanany Elsaid Elanany, Mohamed Tarek ElSayegh, Aly Sherif Hassaballa, Mohammed Abdel-Gayed Abstract Surgery-based multimodality therapies for treatment of malignant pleural mesothelioma have been clinically explored in the past decades. In this regard, hyperthermic intrathoracic or intrapleural chemotherapy has been used as one…

Read More